Cuidado Farmacêutico na Atenção Primária no Brasil em comparação com a Espanha e Reino Unido – Revisão literária

Assumpção, Jéssica; Reis, Sarah Lyssa Martins; Batista, Andressa Paulino; Souza, Layse Fernanda Antonio de; Reis, Ana Carolina Jandotti; Colacite, Jean

doi:10.33448/rsd-v11i13.35029

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several included studies had incomplete data for the cardiovascular risk calculating, and this fact made it difficult to measure the cardiovascular risk for different models and scenarios. If we tried to estimate the cardiovascular risk for different MTM-PC models and scenarios, we would need to perform another review, which certainly would completely change the aim of this review and not evaluate the influence of different models of MTM-PC and other important characteristics of their effects, since there are different instruments to calculate the cardiovascular risk, which must be considered when the calculation is ready in the study, and also there are different diseases that are applied to cardiovascular risk for their management [ 76 , 77 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of Medication Therapy Management by Pharmaceutical Care on Blood Pressure and Cardiovascular Risk in Hypertension: A Systematic Review, Meta-Analysis, and Meta-Regression

et al. 2023

View full text Add to dashboard Cite

Medication therapy management by pharmaceutical care (MTM-PC) has been shown to improve the effectiveness of antihypertensive treatments. The aim was to answer the question: what are the MTM-PC models and their impact on hypertensive patients’ outcomes? This is a systematic review with meta-analysis. The search strategies were run on 27 September 2022 in the following databases: PubMed, EMBASE, Scopus, LILACs, Central Cochrane Library, Web of Science; and International Pharmaceutical Abstracts. The quality and bias risk was assessed by the Downs and Black instrument. Forty-one studies met the eligibility criteria and were included, Kappa = 0.86; 95% CI, 0.66–1.0; (p < 0.001). Twenty-seven studies (65.9%) had MTM-PC models outlined by the clinical team, showing as characteristics the mean of 10.0 ± 10.7 months of follow-up of hypertensive patients, with 7.7 ± 4.9 consultations. Instruments to assess the quality of life measured the enhancement by 13.4 ± 10.7% (p = 0.047). The findings of the meta-analysis show a mean reduction of −7.71 (95% CI, −10.93 to −4.48) and −3.66 (95% CI, −5.51 to −1.80), (p < 0.001) in mmHg systolic and diastolic pressures, respectively. Cardiovascular relative risk (RR) over ten years was 0.561 (95% CI, 0.422 to 0.742) and RR = 0.570 (95% CI, 0.431 to 0.750), considering homogeneous studies, I² = 0%. This study shows the prevalence of MTM-PC models outlined by the clinical team, in which there are differences according to the models in reducing blood pressure and cardiovascular risk over ten years with the improvement in quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%